Status:
COMPLETED
Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents
Lead Sponsor:
Aretaieion University Hospital
Conditions:
Hypertension, Pulmonary
Cardiac Failure
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of this study is to examine and compare the effect of Levosimendan and Milrinone administered intravenously and via inhalation respectively in cardiac surgery patients with pulmonary hypertens...
Detailed Description
Pulmonary hypertension (PH) is a pathophysiological disorder hemodynamically characterized by increased pulmonary vascular resistance and pressure. This can lead to right ventricle pressure overload a...
Eligibility Criteria
Inclusion
- patients with pulmonary hypertension due to left ventricular dysfunction based on echocardiographic diagnosis preoperatively
- elective cardiac surgery
Exclusion
- primary pulmonary hypertension
- thromboembolic disease
- chronic obstructive pulmonary disease
- emergency surgery
- redo surgery
- inability to consent to the study
Key Trial Info
Start Date :
January 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04718350
Start Date
January 27 2021
End Date
December 30 2023
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Onassis Cardiac Surgery Center
Athens, Greece, 17674